Journal: Revista de Saúde Pública

Article Title: Prevalence of hepatitis among young men who have sex with men and transgender women in Brazil

doi: 10.11606/s1518-8787.2024058005555

Figure Lengend Snippet: Profile of viral hepatitis markers in PrEP 15-19 participants, February 2019 to June 2021.

Article Snippet: The antibodies against HAV (anti-HAV IgG and anti-HAV IgM), HBV (total anti-hepatitis B core antibody (HBc) and anti-HBs), and HCV (total anti-HCV) were evaluated using the enzyme-linked immunosorbent assay (Dia.pro Diagnostic Bioprobes Srl).

Techniques:

Journal: Journal of Clinical and Translational Hepatology

Article Title: Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss

doi: 10.14218/JCTH.2021.00496

Figure Lengend Snippet: Comparison of sCD163 levels in 24 healthy subjects (HS), 97 treatment-naïve patients with chronic hepatitis B (CHB), 18 with spontaneous hepatitis B surface antigen (HBsAg) loss (SL), and 31 with treatment-related HBsAg loss (TL). Plasma sCD163 levels were measured by enzyme-linked immunosorbent assays. P -values from Kruskal-Wallis tests adjusted for multiple comparisons. Significant p ≤0.05 in italic . Data are means±SEM.

Article Snippet: HBsAg, hepatitis B e-antigen (HBeAg), anti-HBs, anti-HBe, and hepatitis B core antibody (anti-HBc) were determined with a chemiluminescent microparticle immunoassay (Abbott Architect; Abbott Laboratories, North Chicago, IL, USA).

Techniques:

Journal: Journal of Clinical and Translational Hepatology

Article Title: Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss

doi: 10.14218/JCTH.2021.00496

Figure Lengend Snippet: (A) Plasma sCD163 and ALT. (B) Plasma sCD163 and AST. (C) Plasma sCD163 and total bilirubin. (D) Plasma sCD163 and direct bilirubin. (E) plasma sCD163 levels and PLT. (F) Plasma sCD163 and hepatitis B e-antigen (HBeAg, log 10 ) in CHB patients. (G). sCD163 and HBsAg (log 10 ) in HBeAg(+) CHB patients. (H) sCD163 and hepatitis B virus (HBV) DNA (log 10 ) in HBeAg(+) CHB patients. (I) sCD163 levels and HBsAg (log 10 ) in HBeAg(−) CHB patients. (J) sCD163 levels and HBV DNA (log 10 ) in HBeAg(−) CHB patients. (K) sCD163 level in HBV DNA <10 6 IU/mL and HBV DNA≥10 6 IU/mL. (L) sCD163 level in HBV genotypes B and C. (M) sCD163 in HBeAg(+) and HBeAg(−) patients. Comparison (Mann-Whitney test and Spearman’s rank correlation. Data are means±SEM. p -values ≤0.05 are in italic . CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; sCD163, soluble CD163; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; PLT, platelet count.

Article Snippet: HBsAg, hepatitis B e-antigen (HBeAg), anti-HBs, anti-HBe, and hepatitis B core antibody (anti-HBc) were determined with a chemiluminescent microparticle immunoassay (Abbott Architect; Abbott Laboratories, North Chicago, IL, USA).

Techniques: MANN-WHITNEY

Journal: Journal of Clinical and Translational Hepatology

Article Title: Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss

doi: 10.14218/JCTH.2021.00496

Figure Lengend Snippet: (A) Patients with no or mild inflammation and fibrosis (A<2 and F<2) and patients with moderate or severe inflammation or fibrosis (A≥2 or F≥2). B. Patients with substantial inflammation (A≥2) and patients with no or mild inflammation (A<2) (C) Patients with substantial fibrosis (F≥2) and patients with no or portal fibrosis without septa (F<2). (D) Patients with no or mild inflammation (A<2) and patients with substantial inflammation (A≥2) and normal ALT levels. (E) Patients with no or mild inflammation (A<2) and patients with substantial inflammation (A≥2) and abnormal ALT levels (F) Patients with no significant fibrosis (F<2) and patients with substantial fibrosis (F≥2) and normal ALT levels. (G) Patients with no significant fibrosis (F<2) and patients with substantial fibrosis (F≥2) and abnormal ALT levels. Data are means±SEM, Mann-Whitney test, p -values <0.05 are in italic . HBV, hepatitis B virus; sCD163, soluble CD163; ALT, alanine aminotransferase.

Article Snippet: HBsAg, hepatitis B e-antigen (HBeAg), anti-HBs, anti-HBe, and hepatitis B core antibody (anti-HBc) were determined with a chemiluminescent microparticle immunoassay (Abbott Architect; Abbott Laboratories, North Chicago, IL, USA).

Techniques: MANN-WHITNEY

Journal: Journal of Clinical and Translational Hepatology

Article Title: Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss

doi: 10.14218/JCTH.2021.00496

Figure Lengend Snippet: (A) CD14 + CD16 − . (B) CD14 + CD16 + . (C) CD14 − CD16 + . (D) Comparison of the MFI of CD163 expression on classical (CD14 + CD16 − CD163 + ) and intermediate (CD14 + CD16 + CD163 + ) monocyte subsets in healthy subjects, treatment-naïve CHB patients, patients with spontaneous HBsAg loss, and patients with treatment-related HBsAg loss. Data are means±SEM. p -values <0.05 are in italic . CHB, chronic hepatitis B; HBsAg, hepatitis B surface antigen; sCD163, soluble CD163.

Article Snippet: HBsAg, hepatitis B e-antigen (HBeAg), anti-HBs, anti-HBe, and hepatitis B core antibody (anti-HBc) were determined with a chemiluminescent microparticle immunoassay (Abbott Architect; Abbott Laboratories, North Chicago, IL, USA).

Techniques: Expressing

Journal: Journal of Clinical and Translational Hepatology

Article Title: Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss

doi: 10.14218/JCTH.2021.00496

Figure Lengend Snippet: (A) Receiver operating characteristic (ROC) curve analysis for identifying patients with significant inflammation (A≥2) by the sCD163, ALT, AST, HBsAg, or HBV DNA level. (B) ROC curve analysis for identifying patients with significant inflammation (A≥2) by combining the sCD163, ALT, and AST levels. (C) ROC curve analysis to identify patients with significant fibrosis (F≥2) by the sCD163, GPR, RPR, APRI, or FIB-4 level. (D) ROC curve analysis for identifying patients with significant fibrosis (F≥2) by combining the sCD163, ALT and, AST levels. HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; sCD163, soluble CD163; ALT, alanine aminotransferase; AST, Aspartate aminotransferase; RPR, red cell distribution width to platelet ratio; APRI, aspartate aminotransferase-to-platelet ratio index; FIB-4, fibrosis-4.

Article Snippet: HBsAg, hepatitis B e-antigen (HBeAg), anti-HBs, anti-HBe, and hepatitis B core antibody (anti-HBc) were determined with a chemiluminescent microparticle immunoassay (Abbott Architect; Abbott Laboratories, North Chicago, IL, USA).

Techniques:

Journal: Journal of Clinical and Translational Hepatology

Article Title: Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss

doi: 10.14218/JCTH.2021.00496

Figure Lengend Snippet: (A) Comparison of baseline sCD163 levels in antiviral treatment responders and nonresponders based on no detectable HBV DNA undetectable. (B) Comparison of baseline sCD163 levels in antiviral treatment responders and nonresponders based on an HBsAg decline >1 log 10 IU/mL (C) Comparison of baseline sCD163 levels in antiviral treatment responders and nonresponders based on an HBeAg decline >1 log 10 signal/cutoff ratio. Mann-Whitney test; p -values adjusted for multiple comparisons. p -values ≤0.05 are in italic . Data are means±SEM. HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; sCD163, soluble CD163.

Article Snippet: HBsAg, hepatitis B e-antigen (HBeAg), anti-HBs, anti-HBe, and hepatitis B core antibody (anti-HBc) were determined with a chemiluminescent microparticle immunoassay (Abbott Architect; Abbott Laboratories, North Chicago, IL, USA).

Techniques: MANN-WHITNEY